Newsroom
Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.
The Future Of Inflammation: The Inflammasome And Beyond
In Vivo
Introducing Fierce Biotech’s 2024 Fierce 15
Fierce Biotech
Breaking the Cycle of Inflammation in Parkinson’s Disease
BioSpace
What do Parkinson’s and obesity have in common?
STAT
NodThera’s NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial
Fierce Biotech
NodThera’s NT-0796 Shows Promise as Parkinson Disease Treatment in Phase 1b/2a Trial
Neurology Live